Drawing for PES

USPTO serial 79035934

PES

Reviewed by CopyMark Law Group

Reg. 3499258Status 404
Filing date
Status date
Registration date
Sep 9, 2008
Examiner
PEREZ, STEVEN M
Law office
MADRID PROCESSING UNIT

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with PES?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Kenneth F. Florek

Kenneth F. Florek FLOREK & ENDRES PLLC1156 Avenue of the AmericasSuite 600New York, NY 10036-2702

Goods and services

ClassDescriptionStatusFirst use
003Essential oils; plant extracts for use as cosmetics, hair lotions and perfumery; cosmeticsSECTION 71 - CANCELLED—
005Pharmaceutical, veterinary and sanitary preparations for use in the treatment of infection of respiratory tract, infection of urinary tract, urinary obstruction, chronical venous insufficiency, prostate hyperplasia, muscle pains, soft tissue rheumatism, musculoskeletal disease, liver disease, hepatitis, cirrhosis of the liver; pharmaceutical preparations for the use in the treatment of angina, atherosclerosis, bronchial asthma, circulatory disorders, constipation, diarrhea, heart failure, heart rhythm disorders, high blood pressure, indigestion, insomnia, migraine, motion sickness, nausea, peptic ulcers, vomiting and allergy; pharmaceutical preparations, namely, plant extracts for use as an antidepressant, diuretic, hypnotic, sedative, stimulant and tranquilizer; hemorrhoidal ointment, laxative, nasal decongestant capsules, nasal spray preparation, non-narcotic analgesic, throat lozenges; medicaments for the treatment of gynecological disorders; medicinal preparations in tablet form, namely, tablets for regulating menstruation circulation; drugs for treatment of circulatory organ ailments; hormone preparations for medical use;medicinal preparations for treatment of ailments of the urinary, genital and anal organs; medicinal preparations for treatment of blood diseases and disorders; oriental medicine for the treatment of gynecologic disorders; pills for treating dizziness; immune regulators, namely, medicinal preparations for the strengthening of the immune system; pharmaceutical preparations and medicines for the treatment of women's diseases, namely, migraine and depression; medicines for the treatment of breast pain; pharmaceutical preparations and medicines for the treatment of gynecological disorders affecting menstruation, sterility, menstruous syndromes, mammae, mastopathy, mastodynia, climacteric complaints, premenstrual syndrome, dysmenorrhea; health food, namely, food for diabetics; dietetic substances adapted for medical use, namely, food for medically restricted diets, food for diabetics, dietary food supplements, vitamin and mineral supplements, herb teas for medicinal purposes and medicinal teas; plant extracts, tinctures and aromatic substances in liquid, solid or gaseous form for pharmaceutical preparations and for dietetic substances for medical use, namely, medicinal herb extracts; nutritional additives for medical purposes for use in foods and dietary supplements for human and animal consumption; dietetic supplements in the form of tablets, drops, capsules, extract preparations, balms and/or in liquid form, containing plant extracts for the treatment of infection of respiratory tract,infection of urinary tract, urinary obstruction, chronical venous insufficiency, prostate hyperplasia, muscle pains, soft tissue rheumatism, musculoskeletal disease, liver disease, hepatitis, cirrhosis of the liver, angina, atherosclerosis, bronchial asthma, circulatory disorders,constipation, diarrhea, heart failure, heart rhythm disorders, high blood pressure, indigestion, insomnia, migraine, motion sickness, nausea, peptic ulcers, vomiting and allergy, women's diseases, namely, migraine and depression, breast pain, gynecological disorders affecting menstruation, sterility, menstruous syndromes, mammae, mastopathy, mastodynia climacteric complaints, premenstrual syndrome, dysmenorrhea; dietetic supplements in the form of tablets, drops, capsules, extract preparations, balms and/or in liquid form, containing plant extracts for use as an antidepressant, diuretic, hypnotic, sedative, stimulant and tranquilizer,hemorrhoidal ointment, laxative, nasal decongestant capsules, nasal spray preparation, non-narcotic analgesic, throat lozenges; dietetic supplements in the form of tablets, drops, capsules, extract preparations, balms and/or in liquid form, containing plant extracts for the treatment of gynecological disorders; dietetic food supplements; mineral food supplements, food supplements based on amino acids, minerals and/or trace elementsSECTION 71 - CANCELLED—
029Plant extracts, tinctures and flavorings for foodstuffs, food supplements and food, namely, protein and fat based extracts for soupsSECTION 71 - CANCELLED—
030Plant extracts, tinctures and flavorings for non-medical food purposes, namely, grain based food flavorings and grain based extracts used as a flavoringSECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jan 12, 2017DENCNOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED—
Jan 12, 2017DETHDEATH OF INTERNATIONAL REGISTRATION—
Aug 19, 2016INNTTOTAL INVALIDATION PROCESSED BY THE IB—
Feb 19, 2016INTSTOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Feb 18, 2016INPCINVALIDATION PROCESSED—
Dec 10, 2015INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
Apr 10, 2015C71TCANCELLED SECTION 71—
Jun 12, 2014NREPNEW REPRESENTATIVE AT IB RECEIVED—
Dec 30, 2012FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Apr 27, 2010TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Mar 19, 2009LIMNLIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED—
Mar 5, 2009LIMGLIMITATION OF GOODS RECEIVED FROM IB—
Jan 6, 2009FICSFINAL DISPOSITION NOTICE SENT TO IB—
Jan 6, 2009FIMPFINAL DISPOSITION PROCESSED—
Dec 9, 2008FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Oct 1, 2008CORNCORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED—
Sep 25, 2008CRCVCORRECTION TRANSACTION RECEIVED FROM IB—
Sep 9, 2008R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jun 24, 2008PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jun 4, 2008NPUBNOTICE OF PUBLICATION—
May 20, 2008PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
May 20, 2008ALIEASSIGNED TO LIE—
May 20, 2008CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Apr 30, 2008ACECAMENDMENT FROM APPLICANT ENTERED—
Apr 30, 2008CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 25, 2008MAILPAPER RECEIVED—
Dec 12, 2007CNFRFINAL REFUSAL MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Dec 11, 2007CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jul 31, 2007ACECAMENDMENT FROM APPLICANT ENTERED—
Jul 31, 2007ALIEASSIGNED TO LIE—
Jul 12, 2007CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 12, 2007MAILPAPER RECEIVED—
May 17, 2007RFNTREFUSAL PROCESSED BY IB—
Apr 25, 2007RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Apr 25, 2007RFRRREFUSAL PROCESSED BY MPU—
Apr 24, 2007RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Apr 23, 2007CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 16, 2007DOCKASSIGNED TO EXAMINER—
Apr 16, 2007NWAPNEW APPLICATION ENTERED—
Apr 12, 2007REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance